克唑替尼治疗ALK重排非小细胞肺癌的共临床定量肿瘤体积成像研究
在8只ALK重排腺癌双转基因小鼠和33例ALK重排非小细胞肺癌患者中,于克唑替尼治疗期间系列影像定量肿瘤体积负荷,比较两者体积变化与最大缓解时间。小鼠最大缓解时中位肿瘤体积缩小40.4%,患者缩小72.9%(Wilcoxon p=0.03);小鼠最大缓解中位时间6周,患者15.7周;总体体积缓解率小鼠50%、患者97%。
要点
- 克唑替尼治疗ALK重排NSCLC,患者最大缓解时中位肿瘤体积缩小72.9%,小鼠为40.4%(Wilcoxon p=0.03)。
- 患者最大缓解中位时间15.7周,小鼠6周;患者总体体积缓解率97%,小鼠50%。
- 患者队列中位治疗时间13.1个月,体积变化蜘蛛图显示持久缓解。
核心结论
- 本研究初步比较了基因匹配的小鼠与人类ALK重排NSCLC队列在克唑替尼治疗期间的定量肿瘤体积负荷变化,两个队列最大体积缓解程度存在差异,提示需进一步研究以优化共临床试验设计与解读。
研究设计与样本
- 共临床影像研究:8只ALK重排腺癌双转基因小鼠和33例ALK重排NSCLC患者接受克唑替尼治疗,于系列影像研究上定量肿瘤体积负荷,比较小鼠与人类的体积肿瘤负荷变化及最大缓解时间。
关键影像表现/征象
- 小鼠最大缓解时中位肿瘤体积缩小40.4%(范围-79.5%至+11.7%)。
- 人类最大缓解时中位肿瘤体积缩小72.9%(范围-100%至+72%),较小鼠降幅更大(Wilcoxon p=0.03)。
- 小鼠从治疗开始至最大缓解的中位时间为6周,人类为15.7周。
- 人类队列体积变化蜘蛛图显示持久缓解,中位治疗时间13.1个月。
诊断标准与关键数值
- 总体体积缓解率:小鼠50%,人类97%。
- 最大缓解时中位肿瘤体积变化:小鼠-40.4%(范围-79.5%至+11.7%),人类-72.9%(范围-100%至+72%),组间比较Wilcoxon p=0.03。
- 治疗开始至最大缓解中位时间:小鼠6周,人类15.7周。
临床应用与阅片要点
- 在ALK重排NSCLC克唑替尼治疗中,定量肿瘤体积成像可评估体积负荷变化,患者最大缓解中位时间15.7周、中位治疗时间13.1个月。
- 共临床影像比较显示小鼠与人类最大体积缓解程度存在差异(小鼠中位缩小40.4% vs 人类72.9%),解读动物模型结果时需考虑此差异。
局限性
- 原文结论指出需进一步研究以优化共临床试验设计与解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate and compare the volumetric tumor burden changes during crizotinib therapy in mice and human cohorts with ALK-rearranged non-small-cell lung cancer (NSCLC).
METHODS: Volumetric tumor burden was quantified on serial imaging studies in 8 bitransgenic mice with ALK-rearranged adenocarcinoma treated with crizotinib, and in 33 human subjects with ALK-rearranged NSCLC treated with crizotinib. The volumetric tumor burden changes and the time to maximal response were compared between mice and humans.
RESULTS: The median tumor volume decrease (%) at the maximal response was -40.4% (range: -79.5%-+11.7%) in mice, and -72.9% (range: -100%-+72%) in humans (Wilcoxon p=0.03). The median time from the initiation of therapy to maximal response was 6 weeks in mice, and 15.7 weeks in humans. Overall volumetric response rate was 50% in mice and 97% in humans. Spider plots of tumor volume changes during therapy demonstrated durable responses in the human cohort, with a median time on therapy of 13.1 months.
CONCLUSION: The present study described an initial attempt to evaluate quantitative tumor burden changes in co-clinical imaging studies of genomically-matched mice and human cohorts with ALK-rearranged NSCLC treated with crizotinib. Differences are noted in the degree of maximal volume response between the two cohorts in this well-established paradigm of targeted therapy, indicating a need for further studies to optimize co-clinical trial design and interpretation.
引用
- Nishino M, Sacher AG, Gandhi L, et al. Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib. Eur J Radiol. 2016. PMID: 28189201. doi:10.1016/j.ejrad.2016.12.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。